Reports Q3 revenue $23.4M, consensus $22.72M. “We are pleased to announce record net revenue of $23.4 million, a significant decrease in our net loss and record Adjusted EBITDA in our first full quarter selling both ILUVIEN and YUTIQ,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer. “We believe we are already seeing an impact of the expanded sales team selling both ILUVIEN and YUTIQ and are on track to deliver over $100 million in net revenue and more than $20 million in Adjusted EBITDA in 2024. We are excited by the opportunities for sustained sales growth of both YUTIQ and ILUVIEN and we are actively evaluating indication expansion opportunities to broaden the number of patients that either long-acting steroid implant can help treat. We expect to share more on these possibilities in the coming months.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALIM:
- Alimera Sciences Reports Third Quarter 2023 Results
- ALIM Earnings this Week: How Will it Perform?
- Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress
- Alimera Sciences appoints Jason Werner as COO
- Alimera Sciences Appoints Jason Werner as Chief Operating Officer